HUTCHMED and GSK Sign Deal for Dual-Targeted KRAS-EGFR Cancer Drug
HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.
HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.
The company will continue developing the drug for irritable bowel syndrome (IBS).
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.